| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Stephanos J Hadziyannis | |
| Evangelini Dimou | |||
| Vasilios Papadimitropoulos | |||
| P2860 | cites work | Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B | Q28212394 |
| A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B | Q28266038 | ||
| Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group | Q28370506 | ||
| Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group | Q31405858 | ||
| Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine | Q33206221 | ||
| Hepatitis B: an important public health issue | Q33947147 | ||
| Management of hepatitis B: 2000--summary of a workshop | Q34263265 | ||
| Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. | Q34500537 | ||
| Lamivudine for patients with chronic hepatitis B and advanced liver disease | Q34551713 | ||
| Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. | Q40417514 | ||
| A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. | Q42541246 | ||
| Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy | Q43629454 | ||
| Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. | Q43662700 | ||
| Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. | Q43722501 | ||
| Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years | Q43914060 | ||
| Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. | Q43951673 | ||
| Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease | Q44042298 | ||
| Histological outcome during long-term lamivudine therapy. | Q44269261 | ||
| Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. | Q44329201 | ||
| Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. | Q44709445 | ||
| Long-term safety of lamivudine treatment in patients with chronic hepatitis B. | Q44729211 | ||
| Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. | Q45023133 | ||
| A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. | Q45045460 | ||
| Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. | Q45061899 | ||
| Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine | Q45070061 | ||
| Evolution of multi-drug resistant hepatitis B virus during sequential therapy | Q45412758 | ||
| Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine | Q46552174 | ||
| Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. | Q46575197 | ||
| Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. | Q46575199 | ||
| Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation | Q46707913 | ||
| A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients | Q46757241 | ||
| Virologic response and resistance to adefovir in patients with chronic hepatitis B. | Q46842950 | ||
| A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. | Q46981468 | ||
| Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B | Q57487519 | ||
| Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B | Q59306546 | ||
| Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B | Q70250537 | ||
| Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B | Q71051138 | ||
| Lamivudine as initial treatment for chronic hepatitis B in the United States | Q73098368 | ||
| The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B | Q73700085 | ||
| Hepatitis B virus infection | Q73929492 | ||
| P433 | issue | 6 | |
| P921 | main subject | entecavir | Q418586 |
| chronic hepatitis | Q62019625 | ||
| P304 | page(s) | 1077-1086 | |
| P577 | publication date | 2007-12-01 | |
| P1433 | published in | Therapeutics and Clinical Risk Management | Q15766913 |
| P1476 | title | The role of entecavir in the treatment of chronic hepatitis B. | |
| P478 | volume | 3 |
| Q64053782 | Ciclopirox inhibits Hepatitis B Virus secretion by blocking capsid assembly |
| Q33651263 | Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination |
| Q37378265 | Hepatitis B virus infected health care workers in The Netherlands, 2000-2008. |
| Q40789723 | Molecular diagnosis of entecavir resistance |
| Q60922847 | Switching Lamivudine with Adefovir Dipivoxil Combination Therapy to Entecavir Monotherapy Provides Better Viral Suppression and Kidney Safety |
Search more.